IN2014MN02497A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02497A IN2014MN02497A IN2497MUN2014A IN2014MN02497A IN 2014MN02497 A IN2014MN02497 A IN 2014MN02497A IN 2497MUN2014 A IN2497MUN2014 A IN 2497MUN2014A IN 2014MN02497 A IN2014MN02497 A IN 2014MN02497A
- Authority
- IN
- India
- Prior art keywords
- acceptable salt
- pharmacologically acceptable
- inhibitory action
- kinase enzyme
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention provides a compound useful in treating tumors by ROS1 kinase enzyme activity inhibitory action and NTRK kinase enzyme inhibitory action or a pharmacologically acceptable salt thereof. A compound having an imidazo[1 2 b]pyridazine structure represented by general formula (I) a pharmacologically acceptable salt thereof or pharmaceutical compositions comprising such compounds. (In the formula R G T Y Y Y and Y are as defined in the present description.)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012127079 | 2012-06-04 | ||
| PCT/JP2013/065328 WO2013183578A1 (en) | 2012-06-04 | 2013-06-03 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02497A true IN2014MN02497A (en) | 2015-07-17 |
Family
ID=49711970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2497MUN2014 IN2014MN02497A (en) | 2012-06-04 | 2013-06-03 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9187489B2 (en) |
| EP (1) | EP2857404B1 (en) |
| JP (1) | JP5814467B2 (en) |
| KR (1) | KR101781255B1 (en) |
| CN (1) | CN104520300B (en) |
| AU (1) | AU2013272701B2 (en) |
| BR (1) | BR112014029851B1 (en) |
| CA (1) | CA2874819C (en) |
| CO (1) | CO7160119A2 (en) |
| CY (1) | CY1119607T1 (en) |
| DK (1) | DK2857404T3 (en) |
| ES (1) | ES2648228T3 (en) |
| HR (1) | HRP20171724T1 (en) |
| HU (1) | HUE037221T2 (en) |
| IL (1) | IL236075A (en) |
| IN (1) | IN2014MN02497A (en) |
| LT (1) | LT2857404T (en) |
| MX (1) | MX357021B (en) |
| MY (1) | MY170326A (en) |
| NO (1) | NO2857404T3 (en) |
| NZ (1) | NZ702574A (en) |
| PH (1) | PH12014502721A1 (en) |
| PL (1) | PL2857404T3 (en) |
| PT (1) | PT2857404T (en) |
| RS (1) | RS56625B1 (en) |
| RU (1) | RU2635917C2 (en) |
| SG (1) | SG11201408052WA (en) |
| SI (1) | SI2857404T1 (en) |
| SM (1) | SMT201700539T1 (en) |
| TW (1) | TWI585088B (en) |
| WO (1) | WO2013183578A1 (en) |
| ZA (1) | ZA201408843B (en) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2952692C (en) | 2008-09-22 | 2020-04-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds |
| PT3372605T (en) | 2008-10-22 | 2021-12-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
| SMT201900203T1 (en) | 2010-05-20 | 2019-05-10 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| AU2013268400B2 (en) | 2012-05-30 | 2017-07-13 | Nippon Shinyaku Co., Ltd. | Aromatic heterocyclic derivative and pharmaceutical |
| ES2715676T3 (en) | 2014-03-27 | 2019-06-05 | Janssen Pharmaceutica Nv | Substituted 4,5,6,7-tetrahydro-pyrazolo [1,5-a] pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo [1,5-a] [1,4] diazepine as ros1 inhibitors |
| WO2015144801A1 (en) * | 2014-03-27 | 2015-10-01 | Janssen Pharmaceutica Nv | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS |
| AR100191A1 (en) * | 2014-04-25 | 2016-09-14 | Exelixis Inc | METHOD FOR TREATMENT OF LUNG ADENOCARCINOMA |
| CA2967951C (en) | 2014-11-16 | 2023-11-07 | Array Biopharma, Inc. | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| KR20180021745A (en) | 2015-06-01 | 2018-03-05 | 록쏘 온콜로지, 인코포레이티드 | How to diagnose and treat cancer |
| EP3310441B1 (en) | 2015-06-18 | 2020-07-29 | 89Bio Ltd. | 1, 4-substituted piperidine derivatives |
| JP6986972B2 (en) | 2015-06-18 | 2021-12-22 | エイティナイン バイオ リミテッド | Substituted 4-benzyl and 4-benzoylpiperidin derivatives |
| SI3322706T1 (en) | 2015-07-16 | 2021-04-30 | Array Biopharma, Inc. | Substituted pyrazolo(1,5-a)pyridine compounds as ret kinase inhibitors |
| CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| CN106854174A (en) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | A kind of preparation method of 4 substituted piperidine derivatives |
| PH12018502124B1 (en) | 2016-04-04 | 2024-04-12 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| JP7057343B2 (en) | 2016-04-04 | 2022-04-19 | ロクソ オンコロジー， インコーポレイテッド | How to treat childhood cancer |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| PT3458456T (en) | 2016-05-18 | 2020-12-07 | Array Biopharma Inc | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide |
| CN107400082A (en) * | 2016-05-19 | 2017-11-28 | 湖南华腾制药有限公司 | A kind of preparation method of substituted piperidine derivative |
| TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| JOP20190072A1 (en) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors |
| JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| JP7082608B2 (en) * | 2017-03-14 | 2022-06-08 | 第一三共株式会社 | Method for producing 3,6-di-substituted imidazole [1,2-b] pyridazine derivative |
| JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| TWI876442B (en) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
| TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
| US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| CN109748902B (en) * | 2017-11-02 | 2020-11-06 | 杭州科巢生物科技有限公司 | A kind of preparation method of Anlotinib hydrochloride |
| WO2019107671A1 (en) * | 2017-11-29 | 2019-06-06 | 서울대학교 산학협력단 | Anti-ros1 antibody and use thereof |
| CN108129288B (en) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | Synthesis method of trans-3-hydroxycyclobutylformic acid |
| JP6997876B2 (en) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3095366A1 (en) | 2018-03-29 | 2019-10-03 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| JP7174143B2 (en) | 2018-07-24 | 2022-11-17 | 大鵬薬品工業株式会社 | Heterobicyclic compounds that inhibit SHP2 activity |
| US12109193B2 (en) | 2018-07-31 | 2024-10-08 | Loxo Oncology Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
| ES2922314T3 (en) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Fused Heterocyclic Compounds as RET Kinase Inhibitors |
| JP2022515198A (en) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolo [1,5-a] pyridine compound as an inhibitor of FGFR tyrosine kinase |
| US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
| TW202100526A (en) | 2019-03-06 | 2021-01-01 | 日商第一三共股份有限公司 | Pyrrolopyrazole derivatives |
| JP2022526713A (en) | 2019-03-21 | 2022-05-26 | オンクセオ | Dbait molecule in combination with a kinase inhibitor for the treatment of cancer |
| MX2021013576A (en) * | 2019-05-08 | 2021-12-15 | Tyk Medicines Inc | Compound used as kinase inhibitor and application thereof. |
| GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| JP2023500906A (en) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | Methods of treating cancers with acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AR122159A1 (en) * | 2020-05-28 | 2022-08-17 | Novartis Ag | MLL1 INHIBITORS AND ANTINEOPLASTIC AGENTS |
| CN114957259A (en) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | Cyano-substituted aromatic bicyclic compound and application thereof |
| US20240309007A1 (en) * | 2021-07-01 | 2024-09-19 | Anheart Therapeutics (Hangzhou) Co., Ltd. | Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof |
| WO2023220967A1 (en) * | 2022-05-18 | 2023-11-23 | Anheart Therapeutics (Hangzhou) Co., Ltd. | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds |
| CN114989176B (en) * | 2022-07-08 | 2024-08-27 | 深圳市新樾生物科技有限公司 | Imidazopyridazine derivative and application thereof |
| CN115197115B (en) * | 2022-08-25 | 2024-11-08 | 成都金博汇康医药科技有限公司 | Preparation method and application of chiral 5-oxo pyrrolidine-3-carboxylic acid |
| KR20250056969A (en) | 2022-09-07 | 2025-04-28 | 수저우 랑루이 바이오파마슈티컬 씨오 엘티디 | Macrocyclic imidazo[1,2-b]pyridazine derivatives and their preparation methods and uses |
| CN117659020A (en) * | 2022-09-07 | 2024-03-08 | 苏州朗睿生物医药有限公司 | An imidazo[1,2-b]pyridazine derivative and its preparation method and use |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
| JP2004508366A (en) | 2000-09-01 | 2004-03-18 | グラクソ グループ リミテッド | Oxindole derivatives |
| EP1339680A1 (en) | 2000-09-01 | 2003-09-03 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| JP2003231687A (en) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | Pyrazolyl condensed ring compound and pharmaceutical use thereof |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| US20090227648A1 (en) | 2004-04-21 | 2009-09-10 | Astrazeneca Ab | Pyrazole derivatives useful for the treatment of cancer |
| EP1832588A4 (en) * | 2004-12-28 | 2009-09-02 | Takeda Pharmaceutical | IMIDAZOLE CONDENSE DERIVATIVE AND APPLICATIONS THEREOF |
| ES2555063T3 (en) | 2005-02-04 | 2015-12-28 | Astrazeneca Ab | Pyrazolilaminopyridine derivatives useful as kinase inhibitors |
| ES2308731T3 (en) | 2005-02-16 | 2008-12-01 | Astrazeneca Ab | CHEMICAL COMPOUNDS. |
| ATE473975T1 (en) | 2005-02-16 | 2010-07-15 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| JP2009502734A (en) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Fused heterocycles as Lck inhibitors |
| WO2007014707A1 (en) * | 2005-08-01 | 2007-02-08 | F. Hoffmann-La Roche Ag | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
| DE102005042742A1 (en) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals |
| DE102006029447A1 (en) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituted imidazo [1,2b] pyridazines, their preparation and use as pharmaceuticals |
| AU2007315234A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| MX2009004700A (en) * | 2006-11-06 | 2009-05-15 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors. |
| WO2008072682A1 (en) | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | Imidazo[1,2-b]pyridazine derivative |
| JP2009227599A (en) * | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | Imidazopyridazine derivative |
| AU2009246687B2 (en) * | 2008-05-13 | 2012-08-09 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| CA2952692C (en) * | 2008-09-22 | 2020-04-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds |
| KR101147550B1 (en) * | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 2,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors |
| JPWO2012005299A1 (en) | 2010-07-07 | 2013-09-05 | 日本新薬株式会社 | ROS tyrosine kinase inhibitor |
| WO2012125667A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
-
2013
- 2013-05-31 TW TW102119261A patent/TWI585088B/en active
- 2013-06-03 NO NO13801320A patent/NO2857404T3/no unknown
- 2013-06-03 JP JP2014519977A patent/JP5814467B2/en active Active
- 2013-06-03 DK DK13801320.6T patent/DK2857404T3/en active
- 2013-06-03 ES ES13801320.6T patent/ES2648228T3/en active Active
- 2013-06-03 WO PCT/JP2013/065328 patent/WO2013183578A1/en not_active Ceased
- 2013-06-03 RU RU2014153627A patent/RU2635917C2/en active
- 2013-06-03 BR BR112014029851-3A patent/BR112014029851B1/en active IP Right Grant
- 2013-06-03 CA CA2874819A patent/CA2874819C/en active Active
- 2013-06-03 RS RS20171198A patent/RS56625B1/en unknown
- 2013-06-03 MY MYPI2014003346A patent/MY170326A/en unknown
- 2013-06-03 SG SG11201408052WA patent/SG11201408052WA/en unknown
- 2013-06-03 HR HRP20171724TT patent/HRP20171724T1/en unknown
- 2013-06-03 LT LTEP13801320.6T patent/LT2857404T/en unknown
- 2013-06-03 PL PL13801320T patent/PL2857404T3/en unknown
- 2013-06-03 PT PT138013206T patent/PT2857404T/en unknown
- 2013-06-03 HU HUE13801320A patent/HUE037221T2/en unknown
- 2013-06-03 MX MX2014014803A patent/MX357021B/en active IP Right Grant
- 2013-06-03 KR KR1020147033351A patent/KR101781255B1/en active Active
- 2013-06-03 US US14/378,318 patent/US9187489B2/en active Active
- 2013-06-03 CN CN201380041498.XA patent/CN104520300B/en active Active
- 2013-06-03 SM SM20170539T patent/SMT201700539T1/en unknown
- 2013-06-03 NZ NZ702574A patent/NZ702574A/en unknown
- 2013-06-03 EP EP13801320.6A patent/EP2857404B1/en active Active
- 2013-06-03 AU AU2013272701A patent/AU2013272701B2/en active Active
- 2013-06-03 IN IN2497MUN2014 patent/IN2014MN02497A/en unknown
- 2013-06-03 SI SI201330798T patent/SI2857404T1/en unknown
-
2014
- 2014-12-02 ZA ZA2014/08843A patent/ZA201408843B/en unknown
- 2014-12-04 IL IL236075A patent/IL236075A/en active IP Right Grant
- 2014-12-04 PH PH12014502721A patent/PH12014502721A1/en unknown
- 2014-12-30 CO CO14286593A patent/CO7160119A2/en unknown
-
2015
- 2015-10-29 US US14/926,973 patent/US9751887B2/en active Active
-
2017
- 2017-11-15 CY CY20171101204T patent/CY1119607T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02497A (en) | ||
| PH12015500064A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| PH12013501758A1 (en) | Pyrazolo [1,5-a] pyridines as trk inhibitors | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| HK1211942A1 (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| PH12016501813B1 (en) | 1,3-benzodioxole derivative | |
| UA117976C2 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| PH12014500883A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| GEP201606555B (en) | Compounds and compositions for modulating egfr activity | |
| MY172924A (en) | Neprilysin inhibitors | |
| WO2014031438A3 (en) | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| PH12015500211A1 (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
| EA024194B8 (en) | Diarylacetylene hydrazide containing tyrosine kinase inhibitors | |
| WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
| PH12014501979B1 (en) | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor | |
| MX340574B (en) | Imidazo pyrazines. | |
| UA111210C2 (en) | ANTIBACTERIAL 3,4-DIGIDRO-1H- [1,8] NAFTYRIDINONS, CYCLOPENT SUBSTITUTED [C] PYROM | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| MX2013007937A (en) | Novel indole or indazole derivative or salt thereof. | |
| PH12015501146A1 (en) | Hydantoin derivative | |
| TN2012000370A1 (en) | 5-alkynyl pyrimidines and their use as kinase inhibitors | |
| MY187891A (en) | Tetrahydropyridine derivatives as fabi inhibitors | |
| HK1219736A1 (en) | Arginine methyltransferase inhibitors and uses thereof |